Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 10/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.33 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26502448 | 1.00 | PANK3 (0.49) | PANK3PTGS1PTGS2RETCACNA1G | |
| SCHEMBL31717534 | 0.88 | PANK3 (0.64) | PANK3RET | |
| SCHEMBL19747958 | 0.88 | PANK3 (0.64) | PANK3RET | |
| SCHEMBL21406136 | 0.88 | PANK3 (0.64) | PANK3RET | |
| SCHEMBL31717844 | 0.88 | PANK3 (0.64) | PANK3RET | |
| SCHEMBL26501539 | 0.84 | PANK3 (0.45) | PANK3RETCACNA1GCACNA1HCACNA1I | |
| SCHEMBL26501538 | 0.84 | PANK3 (0.45) | PANK3RETCACNA1GCACNA1HCACNA1I | |
| SCHEMBL26501531 | 0.84 | PANK3 (0.45) | PANK3RETCACNA1GCACNA1HCACNA1I | |
| SCHEMBL26501572 | 0.84 | PANK3 (0.45) | PANK3RETCACNA1GCACNA1HCACNA1I | |
| SCHEMBL26501535 | 0.84 | PANK3 (0.52) | PANK3GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885PTGS1 2068/4885PTGS2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.